Company / SG&A Expense
Axsome Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$570.6M
FY2025
5-year range
$66.6M / $570.6M
FY2021-FY2025
Trend
+38.7%
vs FY2024
Sector context
#31 of 213
Health Care
What the data says
Axsome Therapeutics, Inc.'s sg&a expense of $571M is higher than 85% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 9 consecutive years, from $6M in FY2016 to $571M in FY2025.
Based on SEC 10-K filings.
$571M in FY2025 with a 5-year CAGR of +81.6%. Top quartile in the Health Care sector.
Increased from $323M to $571M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +53.0%
- 5-Year CAGR
- +81.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 213This company $570.6M Sector average $722.3M
▼
-21.0% below sector average
Key checks
Key Insights
- Axsome Therapeutics, Inc.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +81.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 38.7% year-over-year.
- Ranks #31 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $570.6M | +38.7% |
| FY2024 | $411.4M | +27.3% |
| FY2023 | $323.1M | +102.9% |
| FY2022 | $159.3M | +139.0% |
| FY2021 | $66.6M | +130.6% |
| FY2020 | $28.9M | +112.5% |
| FY2019 | $13.6M | +45.4% |
| FY2018 | $9.4M | +29.8% |
| FY2017 | $7.2M | +13.6% |
| FY2016 | $6.3M | +162.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026